A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer
Phase 1 Withdrawn
Study to Evaluate Safety and Dosimetry of [18F]GEH121224 in Patients With Locally Advanced or Metastatic Breast Cancer
Phase 1 Withdrawn
Study of OB-002 in Patients With Refractory Metastatic Cancer
Phase 1 Withdrawn
Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201
Phase 1 Withdrawn
Molecular Neuroimaging to Assess the Link Between Neuroinflammation and Cognitive Impairment in Breast Cancer
Phase 1 Withdrawn
A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Withdrawn
Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis
Phase 1 Withdrawn
Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial
Phase 1 Withdrawn
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
Phase 1 Withdrawn
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.
Phase 1 Withdrawn
Vaccine Response With NT-I7
Phase 1 Withdrawn
A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer
Phase 1 Withdrawn
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
Phase 1 Withdrawn
Implantable Microdevice for TNBC - Pilot Study
Phase 1 Withdrawn
A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer
Phase 1 Withdrawn
LABC
Phase 1 Withdrawn
Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors
Phase 1 Withdrawn
AIPAC-002
Phase 1 Withdrawn
Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer
Phase 1 Withdrawn
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
Phase 1 Withdrawn
Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases
Phase 1 Withdrawn
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
Phase 1 Withdrawn
LCCC1820
Phase 1 Withdrawn
Tucatinib + Abemaciclib + Herceptin for HER2+ MBC
Phase 1 Withdrawn
Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer
Phase 1 Withdrawn
To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast Cancer
Phase 1 Withdrawn
Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer
Phase 1 Withdrawn
Imaging With [11C]Martinostat in Breast Cancer
Phase 1 Withdrawn
rVV-740CTA
Phase 1 Withdrawn
MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer
Phase 1 Withdrawn
IMGN853
Phase 1 Withdrawn
L-glutamine Supplementation to Alleviate Symptoms of Taxane-Induced Neuropathy in Patients With Breast Cancer
Phase 1 Withdrawn
CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors
Phase 1 Withdrawn
Lenvatinib and Capecitabine in Patients With Advanced Malignancies
Phase 1 Withdrawn
Dose Optimization of Rosuvastatin in Early Stage and Metastatic Estrogen Receptor Positive Breast Cancer Patients on Endocrine Therapy
Phase 1 Withdrawn
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
Phase 1 Withdrawn
Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery
Phase 1 Withdrawn
Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors
Phase 1 Withdrawn
CP-751871 In Treating Women With Early-Stage Breast Cancer That Can Be Removed By Surgery
Phase 1 Withdrawn
18-F-Fluoroacetate as PET Imaging Agent
Phase 1 Withdrawn
Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung
Phase 1 Withdrawn
TNFactor
Phase 1 Withdrawn
Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer
Phase 1 Withdrawn
MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer
Phase 1 Withdrawn
Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer
Phase 1 Withdrawn
Riluzole in Women With Stage I, Stage II, or Stage IIIA Breast Cancer
Phase 1 Withdrawn
Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)
Phase 1 Withdrawn